ReviewActa neurologica Belgica2026
Neuroimaging biomarkers of the brain-heart axis in Takotsubo syndrome: regional convergence without directional consistency: a systematic review and biomarker qualification appraisal.
Review in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTakotsubo syndrome (TTS) is an acute stress-induced cardiomyopathy increasingly recognised as a disorder of the brain-heart axis. Neuroimaging studies have identified structural, functional and metabolic abnormalities within the central autonomic network, particularly the amygdala. Still, the role of amygdalar activity as a biomarker in TTS has not been systematically synthesised.
methodsA systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420251177487). PubMed, Web of Science, Cochrane Library, Google Scholar and ClinicalTrials.gov were searched through February 2025 for studies reporting neuroimaging findings in confirmed TTS. Data were extracted, narratively synthesised, and appraised against biomarker-qualification criteria. Directional consistency was additionally quantified by vote counting with exact binomial (sign) tests at the level of study-region-imaging domain, with Holm correction for multiplicity and sensitivity analyses excluding studies at high risk of bias.
resultsThe search identified 489 records, of which 29 underwent full-text assessment; 10 studies met the inclusion criteria. Multimodal neuroimaging consistently implicated the amygdala, insula, hippocampus, thalamus, anterior cingulate and prefrontal cortex, with reduced amygdalar and insular grey matter, altered limbic structural connectivity, and disrupted central autonomic and default mode network connectivity. Two ¹⁸F-FDG PET/CT cohorts, the only included studies in which imaging preceded the outcome, found raised amygdalar metabolic activity before TTS onset that independently predicted subsequent syndrome development; the remaining eight were cross-sectional and cannot separate predisposition from consequence. Convergent, though directionally inconsistent, evidence supports a working model of chronic limbic sensitisation and exaggerated sympathoadrenal activation contributing to myocardial stunning. Vote counting confirmed that an abnormality was reported by almost every study assessing the amygdala (8/9), insula (6/6), prefrontal cortex (6/6) and hippocampus (5/5), but no region survived correction for multiplicity, and only the prefrontal cortex approached directional consistency (5/5 reduced; p = 0.062); amygdalar findings were directionally split (4 increased versus 3 decreased; p = 1.00). Excluding the two studies at high risk of bias altered no conclusion.
conclusionsNeuroimaging findings support TTS as a neurocardiac disorder characterised by dysfunction of limbic and autonomic brain networks. Amygdalar hyperactivity is the most frequently reported candidate marker of vulnerability, but none of these findings is clinically actionable, and the reasons are specific rather than generic: effect sizes are modest (Cohen's d = 0.37-0.53), the direction of abnormality is inconsistent for every region except the prefrontal cortex, no included study reported test-retest reliability for its own primary measure, no study reported discrimination or calibration, and none tested incremental value over inexpensive psychometric or autonomic measures. These findings are therefore hypothesis-generating; adequately powered prospective cohorts and formal biomarker qualification are required before neuroimaging-guided risk stratification of the brain-heart axis can be considered for clinical use.
Indexed as
Identifiers
42622997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.